| pubmed-article:21544015 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21544015 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:21544015 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21544015 | lifeskim:mentions | umls-concept:C0150369 | lld:lifeskim |
| pubmed-article:21544015 | lifeskim:mentions | umls-concept:C1145759 | lld:lifeskim |
| pubmed-article:21544015 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:21544015 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:21544015 | lifeskim:mentions | umls-concept:C2827666 | lld:lifeskim |
| pubmed-article:21544015 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:21544015 | pubmed:dateCreated | 2011-5-13 | lld:pubmed |
| pubmed-article:21544015 | pubmed:abstractText | Adequate plasma trough concentrations (Ctrough) of protease inhibitors are required to maintain antiviral activity throughout the dosing interval. Therapeutic drug monitoring is used in clinical practice to optimize dosage and avoid toxic or subtherapeutic drug exposure. The pharmacokinetic variability of Atazanavir (ATV) can be relatively large, as a result of several factors. One of the affecting factors may be hepatic impairment due to hepatitis C virus (HCV) coinfection. | lld:pubmed |
| pubmed-article:21544015 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21544015 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21544015 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21544015 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21544015 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21544015 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21544015 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21544015 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21544015 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21544015 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21544015 | pubmed:issn | 1536-3694 | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:D'Arminio... | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:RegazziMarioM | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:TinelliCarmin... | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:MaseratiRenat... | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:SighinolfiLau... | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:BarassiAlessa... | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:VillaniPaolaP | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:CusatoMariaM | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:Melzi... | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:GulminettiRob... | lld:pubmed |
| pubmed-article:21544015 | pubmed:author | pubmed-author:BrandoliniMic... | lld:pubmed |
| pubmed-article:21544015 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21544015 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:21544015 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21544015 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21544015 | pubmed:pagination | 303-8 | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:meshHeading | pubmed-meshheading:21544015... | lld:pubmed |
| pubmed-article:21544015 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21544015 | pubmed:articleTitle | Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens. | lld:pubmed |
| pubmed-article:21544015 | pubmed:affiliation | Clinical Pharmacokinetics Laboratory, Infectious Diseases Department, Clinical Epidemiology and Biometric Unit, Foundation IRCCS S. Matteo Hospital, Pavia, Italy. regazzim@smatteo.pv.it | lld:pubmed |
| pubmed-article:21544015 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21544015 | pubmed:publicationType | Multicenter Study | lld:pubmed |
